TJPC's subsidiary compound potassium hydrogen phosphate injection has passed the consistency evaluation of generic drugs
I'm PortAI, I can summarize articles.
TJPC's subsidiary, Tianjin Jiayao Heping Pharmaceutical Co., Ltd., recently received approval from the National Medical Products Administration for the consistency evaluation of potassium hydrogen phosphate injection as a generic drug. This injection is mainly used to correct hypophosphatemia and for parenteral nutrition. Jiayao Heping submitted a supplementary application for consistency evaluation in July 2024, with a total R&D investment of approximately 9.21 million yuan
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments